Last reviewed · How we verify
Switch ticagrelor to clopidogrel
Clopidogrel is a P2Y12 platelet adenosine diphosphate receptor antagonist that irreversibly inhibits platelet aggregation.
Clopidogrel is a P2Y12 platelet adenosine diphosphate receptor antagonist that irreversibly inhibits platelet aggregation. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Secondary prevention of atherosclerotic events in patients with prior myocardial infarction, stroke, or peripheral arterial disease, Coronary artery disease managed with percutaneous coronary intervention.
At a glance
| Generic name | Switch ticagrelor to clopidogrel |
|---|---|
| Also known as | switch |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | P2Y12 receptor antagonist; antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine prodrug that requires hepatic metabolism to its active form, which then binds irreversibly to the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. This antiplatelet effect reduces thrombotic events in patients with acute coronary syndromes and other atherosclerotic conditions. The switch from ticagrelor (a reversible P2Y12 inhibitor) to clopidogrel represents a change in antiplatelet strategy, typically for reasons of cost, tolerability, or clinical judgment.
Approved indications
- Acute coronary syndrome (unstable angina, NSTEMI, STEMI)
- Secondary prevention of atherosclerotic events in patients with prior myocardial infarction, stroke, or peripheral arterial disease
- Coronary artery disease managed with percutaneous coronary intervention
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Rash
- Gastrointestinal bleeding
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients (PHASE4)
- Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention (PHASE4)
- Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: